Measuring life’s first connection
World leading developer of Male Fertility Medical Devices
Estimates suggest that 48 million couples live with infertility globally.
JUNO-CHECKED®
Diagnoses male-factor infertility to assist the clinician direct to the suitable IVF treatment.
Current commercial methods to analyse the sperm quality only look into the physical aspects of the sperm. Spermosens is developing first of its kind automated sperm diagnostic device JUNO-Checked that relies of their ability to bind to egg cell-proteins. The approach will, for the first time, enable detection of fertilization capacity of sperms, and hence choice of the appropriate IVF treatment method.
Spermosens aims at reducing the conventional iterations in IVF treatments to achieve pregnancy with JUNO-Checked.
Male Infertility
Unfortunately, there has been little progress in methods to diagnose male-factor infertility, and 40% of these cases remain unexplained.
Spermosens aims to empower caregivers and patients alike, helping to understand the cause of male-factor infertility despite seemingly normal sperms.
50%
OF INFERTILITY CASES WITH A MALE FACTOR1
50%
DECREASE IN SPERM COUNT SINCE 1970s IN WESTERN MALES2
40%
UNEXPLAINED MALE INFERTILITY3
More than 3M
IVF CYCLES PERFORMED ANNUALLY GLOBALLY4
Less than 20%
SUCCESS RATES IN ART PER ASPIRATION5
Sources
- https://www.internetmedicin.se/behandlingsoversikter/endokrinologi/infertilitet-manlig/
- https://academic.oup.com/humupd/article/23/6/646/4035689?login=true
- https://pubmed.ncbi.nlm.nih.gov/34183196/
- Whereof 1 million in Europe. https://academic.oup.com/hropen/article/2021/3/hoab026/6342525
- Ref: ESHRE ART Fact Sheet 2022
JUNO-CHECKED®
A patented, user friendly, rapid and small footprint Diagnostic System which predicts the fertilization capacity of sperms. This will assist the clinicians and embryologists to individually decide if the suitable treatment is standard-IVF or ICSI.
Millions of couples waiting in queue for 1-3 years for IVF can now be helped quicker and more economically.
Breakthrough Platform technology
This will lead to an immediate decision if the sperm sample is suitable for standard-IVF or ICSI, thus drastically limiting the number of cycles required for fertilisation and reducing the burden of infertility on the female partner.
SIGN UP AND STAY CONNECTED
Get the latest news by signing up to our newsletter. We welcome you to contact us with any thoughts you may have.
John Lempert
CEO
